GAITHERSBURG, MD--(Marketwire - Oct 23, 2012) - Cytomedix, Inc. (
Houston Stem Cell Summit
Houston, TX, Oct 26 - 27
Presentation Time: 9:50 AM, Friday, October 26th, 2012
Location: The Houstonian Hotel, 111 North Post Oak Lane, Houston, TX
The Houston Stem Cell Summit will bring together, for the first time; the many and varied stem cell research and commercialization activities in Texas with the leading global researchers and entrepreneurs. The latest therapeutic research regarding the use of adult stem and progenitor cell therapies will be featured. The Summit will also provide a forum for entrepreneurs to discuss their latest efforts to commercialize stem cell therapies, and to debate and discuss FDA and other legal and regulatory issues impacting stem cell research and commercialization. Participating Texas institutions include: Baylor College of Medicine, Texas Heart Institute, Texas A&M, Rice University, and MD Anderson. The organizers expect more than 35 speakers, 300 attendees, and participation from a dozen of the leading commercial stem cell companies.
2012 Stem Cell Meeting on the Mesa Investor and Partnering Forum
La Jolla, CA, Oct 29 - 30
Presentation Time: 1:30 PM, Monday October 29th, 2012
Location: Sanford Consortium, 2880 Torrey Pines Scenic Drive, La Jolla, CA
Edward Field will also be a panelist in a discussion "Getting to Market: Keys to Regulatory Success" on October 30th at 2:00pm. This session will examine the regulatory challenges facing regenerative medicine companies and the strategies they employ to reach the market.
The 2012 Stem Cell Meeting on the Mesa is aimed at bringing together senior members of the business development and scientific research communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by more than 600 leading scientists and researchers alongside the regenerative medicine industry's premier annual Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings and further the translation of clinical research.
About Cytomedix, Inc.
Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel™ System, cleared by the FDA for wound care and the Angel® Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.